Thursday, June 27, 2019
Whilst there are a number of risk factors, people who inject drugs bear the burden of Hepatitis C with 95% of new infections occurring within the injecting community. People who inject drugs make up a sizeable proportion of the 25,000 New Zealanders that we estimate are unaware that they may have hepatitis C.
Earlier this year a pan genotypic treatment, Mavriet became freely available and signaled a new era in Hepatitis C testing and treatment in New Zealand . “The funding of Mavriet and availability of this pan genotypic treatment is an absolute game changer and will make an enormous difference in the lives of many in our community”, says Kathryn Leafe, Executive Director. Learn More